These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12883372)

  • 21. Psychotic depression occurring after stopping interferon-alpha.
    Prior TI; Chue PS
    J Clin Psychopharmacol; 1999 Aug; 19(4):385-6. PubMed ID: 10440474
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of basal cell carcinoma with intralesional interferon alpha: a case report and literature review.
    McDonald RR; Georgouras K
    Australas J Dermatol; 1992; 33(2):81-6. PubMed ID: 1294057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clearing of melanoma in situ with intralesional interferon alfa in a patient with xeroderma pigmentosum.
    Turner ML; Moshell AN; Corbett DW; Stern JB; Roth MJ; DiGiovanna J; Horn TD; Kraemer KH
    Arch Dermatol; 1994 Dec; 130(12):1491-4. PubMed ID: 7986121
    [No Abstract]   [Full Text] [Related]  

  • 24. Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies.
    Kirkwood JM
    Eur J Cancer; 1998 Jul; 34 Suppl 3():S12-7. PubMed ID: 9849403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intralesional interferon therapy for basal cell carcinoma.
    Epstein E
    J Am Acad Dermatol; 1992 Jan; 26(1):142-3. PubMed ID: 1732331
    [No Abstract]   [Full Text] [Related]  

  • 26. Complete remission of a primary cutaneous B cell lymphoma treated with intralesional recombinant interferon alpha-2a.
    Zenone T; Catimel G; Barbet N; Clavel M
    Eur J Cancer; 1994; 30A(2):246-7. PubMed ID: 8155398
    [No Abstract]   [Full Text] [Related]  

  • 27. Latest advances in the care of the patient with melanoma.
    White RL; Holder WD
    Ann Surg; 1998 Feb; 227(2):316-7. PubMed ID: 9488537
    [No Abstract]   [Full Text] [Related]  

  • 28. [Role of interferon alfa-2 in melanoma. Results of a phase II study in 27 patients].
    Bernengo MG; Doveil GC; Appino A; Sertoli MR; Ardizzoni A; Vidili MG
    G Ital Dermatol Venereol; 1988 Apr; 123(4):185-8. PubMed ID: 3182009
    [No Abstract]   [Full Text] [Related]  

  • 29. Intralesional interferon-alpha 2b treatment of basal cell carcinoma.
    Thestrup-Pedersen K; Jacobsen IE; Frentz G
    Acta Derm Venereol; 1990; 70(6):512-4. PubMed ID: 1981427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant interferon in the treatment of melanoma.
    Middleton MR
    Br J Cancer; 1999 Aug; 80(11):1679-80. PubMed ID: 10468281
    [No Abstract]   [Full Text] [Related]  

  • 31. A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate.
    Cassel WA; Murray DR
    Med Oncol Tumor Pharmacother; 1992; 9(4):169-71. PubMed ID: 1342060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant therapy of melanoma.
    Retsas S
    Lancet; 1998 Aug; 352(9129):737-8. PubMed ID: 9729017
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of basal cell carcinoma with intralesional interferon.
    Georgouras K
    Australas J Dermatol; 1994; 35(1):47. PubMed ID: 7864996
    [No Abstract]   [Full Text] [Related]  

  • 34. Re: Scientific interest in newcastle disease virus is reviving.
    Csatary LK; Csatary E; Moss RW
    J Natl Cancer Inst; 2000 Mar; 92(6):493-4. PubMed ID: 10716968
    [No Abstract]   [Full Text] [Related]  

  • 35. Adjuvant therapy of melanoma: at what cost?
    Spitler LE
    J Clin Oncol; 2001 Feb; 19(4):1226-8. PubMed ID: 11181688
    [No Abstract]   [Full Text] [Related]  

  • 36. A case of malignant melanoma that developed multiple metastases after switching from interferon-beta to pegylated interferon-alpha-2b as adjuvant therapy.
    Fukumoto T; Fujiwara S; Sakaguchi M; Oka M; Nishigori C
    Eur J Dermatol; 2018 Feb; 28(1):115-116. PubMed ID: 29171409
    [No Abstract]   [Full Text] [Related]  

  • 37. Malignant melanoma: treatments emerging, but early detection is still key.
    Masci P; Borden EC
    Cleve Clin J Med; 2002 Jul; 69(7):529, 533-4, 536-8 passim. PubMed ID: 12109636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [High-dose interferon-alpha and adjuvant treatment of melanoma with poor prognosis: requiem for a drug marketing license?].
    Saiag P
    Ann Dermatol Venereol; 1999 Mar; 126(3):211-3. PubMed ID: 10394432
    [No Abstract]   [Full Text] [Related]  

  • 39. [Immunotherapy of melanoma].
    Dummer R; Nestle FO; Burg G
    Dtsch Med Wochenschr; 2000 Oct; 125(41):1240-2. PubMed ID: 11076264
    [No Abstract]   [Full Text] [Related]  

  • 40. New treatments for melanoma.
    Demierre MF; Allten S; Brown R
    Dermatol Nurs; 2005 Aug; 17(4):287-95. PubMed ID: 16206683
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.